Uterine fibroids

Elizabeth A Stewart, Shannon K Laughlin-Tommaso, William H. Catherino, Sujata Lalitkumar, Devashana Gupta, Beverley Vollenhoven

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Uterine fibroids (also known as leiomyomas or myomas) are common clonal neoplasms of the uterus. Fibroids have both smooth muscle and fibroblast components, in addition to a substantial amount of fibrous extracellular matrix, which all contribute to the pathogenetic process. Fibroids are extremely heterogeneous in their pathophysiology, size, location and clinical symptomatology. They are also a part of a range of disease in which some variants have facets of malignant behaviour but overall are benign. Risk for fibroids is associated with race; black women have a higher risk of developing fibroids earlier in life than their white counterparts and also develop more-severe forms of the disease. Clinically, fibroids account for one-third to half of all hysterectomies and are associated with substantial morbidity and health care costs for women of reproductive age. Indeed, current treatments are primarily surgical and interventional; approximately three-quarters of all fibroid treatments are hysterectomies. However, clinical innovations are emerging in the use of progesterone receptor modulators as a medical therapy. New information is rapidly accumulating about the genetic subgroups that lead to fibroid formation, which might aid further understanding of the clinical heterogeneity of this disease and lead to individualized treatments. This information is a crucial development given the current lack of high-quality evidence on which to base therapeutic decisions.

Original languageEnglish (US)
Article number16043
JournalNature Reviews Disease Primers
Volume2
DOIs
StatePublished - Jun 23 2016

Fingerprint

Leiomyoma
Hysterectomy
Therapeutics
Myoma
Uterine Neoplasms
Progesterone Receptors
Health Care Costs
Extracellular Matrix
Smooth Muscle
Fibroblasts
Morbidity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stewart, E. A., Laughlin-Tommaso, S. K., Catherino, W. H., Lalitkumar, S., Gupta, D., & Vollenhoven, B. (2016). Uterine fibroids. Nature Reviews Disease Primers, 2, [16043]. https://doi.org/10.1038/nrdp.2016.43

Uterine fibroids. / Stewart, Elizabeth A; Laughlin-Tommaso, Shannon K; Catherino, William H.; Lalitkumar, Sujata; Gupta, Devashana; Vollenhoven, Beverley.

In: Nature Reviews Disease Primers, Vol. 2, 16043, 23.06.2016.

Research output: Contribution to journalArticle

Stewart, EA, Laughlin-Tommaso, SK, Catherino, WH, Lalitkumar, S, Gupta, D & Vollenhoven, B 2016, 'Uterine fibroids', Nature Reviews Disease Primers, vol. 2, 16043. https://doi.org/10.1038/nrdp.2016.43
Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nature Reviews Disease Primers. 2016 Jun 23;2. 16043. https://doi.org/10.1038/nrdp.2016.43
Stewart, Elizabeth A ; Laughlin-Tommaso, Shannon K ; Catherino, William H. ; Lalitkumar, Sujata ; Gupta, Devashana ; Vollenhoven, Beverley. / Uterine fibroids. In: Nature Reviews Disease Primers. 2016 ; Vol. 2.
@article{42a8090e9caa4539aef7b1f3468d05c3,
title = "Uterine fibroids",
abstract = "Uterine fibroids (also known as leiomyomas or myomas) are common clonal neoplasms of the uterus. Fibroids have both smooth muscle and fibroblast components, in addition to a substantial amount of fibrous extracellular matrix, which all contribute to the pathogenetic process. Fibroids are extremely heterogeneous in their pathophysiology, size, location and clinical symptomatology. They are also a part of a range of disease in which some variants have facets of malignant behaviour but overall are benign. Risk for fibroids is associated with race; black women have a higher risk of developing fibroids earlier in life than their white counterparts and also develop more-severe forms of the disease. Clinically, fibroids account for one-third to half of all hysterectomies and are associated with substantial morbidity and health care costs for women of reproductive age. Indeed, current treatments are primarily surgical and interventional; approximately three-quarters of all fibroid treatments are hysterectomies. However, clinical innovations are emerging in the use of progesterone receptor modulators as a medical therapy. New information is rapidly accumulating about the genetic subgroups that lead to fibroid formation, which might aid further understanding of the clinical heterogeneity of this disease and lead to individualized treatments. This information is a crucial development given the current lack of high-quality evidence on which to base therapeutic decisions.",
author = "Stewart, {Elizabeth A} and Laughlin-Tommaso, {Shannon K} and Catherino, {William H.} and Sujata Lalitkumar and Devashana Gupta and Beverley Vollenhoven",
year = "2016",
month = "6",
day = "23",
doi = "10.1038/nrdp.2016.43",
language = "English (US)",
volume = "2",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Uterine fibroids

AU - Stewart, Elizabeth A

AU - Laughlin-Tommaso, Shannon K

AU - Catherino, William H.

AU - Lalitkumar, Sujata

AU - Gupta, Devashana

AU - Vollenhoven, Beverley

PY - 2016/6/23

Y1 - 2016/6/23

N2 - Uterine fibroids (also known as leiomyomas or myomas) are common clonal neoplasms of the uterus. Fibroids have both smooth muscle and fibroblast components, in addition to a substantial amount of fibrous extracellular matrix, which all contribute to the pathogenetic process. Fibroids are extremely heterogeneous in their pathophysiology, size, location and clinical symptomatology. They are also a part of a range of disease in which some variants have facets of malignant behaviour but overall are benign. Risk for fibroids is associated with race; black women have a higher risk of developing fibroids earlier in life than their white counterparts and also develop more-severe forms of the disease. Clinically, fibroids account for one-third to half of all hysterectomies and are associated with substantial morbidity and health care costs for women of reproductive age. Indeed, current treatments are primarily surgical and interventional; approximately three-quarters of all fibroid treatments are hysterectomies. However, clinical innovations are emerging in the use of progesterone receptor modulators as a medical therapy. New information is rapidly accumulating about the genetic subgroups that lead to fibroid formation, which might aid further understanding of the clinical heterogeneity of this disease and lead to individualized treatments. This information is a crucial development given the current lack of high-quality evidence on which to base therapeutic decisions.

AB - Uterine fibroids (also known as leiomyomas or myomas) are common clonal neoplasms of the uterus. Fibroids have both smooth muscle and fibroblast components, in addition to a substantial amount of fibrous extracellular matrix, which all contribute to the pathogenetic process. Fibroids are extremely heterogeneous in their pathophysiology, size, location and clinical symptomatology. They are also a part of a range of disease in which some variants have facets of malignant behaviour but overall are benign. Risk for fibroids is associated with race; black women have a higher risk of developing fibroids earlier in life than their white counterparts and also develop more-severe forms of the disease. Clinically, fibroids account for one-third to half of all hysterectomies and are associated with substantial morbidity and health care costs for women of reproductive age. Indeed, current treatments are primarily surgical and interventional; approximately three-quarters of all fibroid treatments are hysterectomies. However, clinical innovations are emerging in the use of progesterone receptor modulators as a medical therapy. New information is rapidly accumulating about the genetic subgroups that lead to fibroid formation, which might aid further understanding of the clinical heterogeneity of this disease and lead to individualized treatments. This information is a crucial development given the current lack of high-quality evidence on which to base therapeutic decisions.

UR - http://www.scopus.com/inward/record.url?scp=85006200799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006200799&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2016.43

DO - 10.1038/nrdp.2016.43

M3 - Article

C2 - 27335259

AN - SCOPUS:85006200799

VL - 2

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

M1 - 16043

ER -